Direction at a glance
Rather than asking one immunogen to produce mature broadly neutralizing antibodies, germline-targeting programmes try to activate rare precursor B cells and guide their maturation through a planned sequence of immunogens.
What the evidence establishes
- Early trials have shown that designed immunogens can activate targeted antibody-precursor classes.
- Separate human studies have induced precursors directed at more than one vulnerable region of the HIV envelope.
- A licensed preventive HIV vaccine does not yet exist.
Next decisive research questions
Limits and responsible interpretation
What this direction does not yet prove
Precursor activation is not the same as protective immunity. The difficult steps are antibody maturation, breadth, durability and practical delivery.
Development pathway
| Decision | Required evidence |
|---|---|
| Biological activity | Target engagement and an outcome that cannot be explained by assay noise or selection. |
| Clinical value | Meaningful benefit, adequate follow-up, safety, comparison with current standard care and transparent uncertainty. |
| Generalizability | Diverse populations, subtypes, geographies, ages and clinically relevant comorbidities. |
| Scalability | Manufacturing, delivery, monitoring, price, workforce and community acceptability. |
Principal sources and evidence gateways
Links checked 18 August 202601
Vaccination induces broadly neutralizing antibody precursors to HIV gp41Nature Immunology · Primary research · Access checked 18 Aug 2026
↗02Vaccination elicits HIV broadly neutralizing antibodies in primatesNature · Primary research · Access checked 18 Aug 2026
↗03NIH HIV/AIDS treatment, prevention and research portalNIH HIVinfo · Research strategy · Access checked 18 Aug 2026
↗04ClinicalTrials.gov HIV study registryU.S. National Library of Medicine · Registry · Access checked 18 Aug 2026
↗